Shionogi linceses ROHTO cell technology for treatment of decompensated cirrhosisCurrently ROHTO Pharmaceutical conducts Phase I/II for 15 patients with decompensated cirrhosis. Treathment is based on a regenerative cell product ADR – 001 that uses allogenic adipose-derived mesenchymal stem cells (MSC).  To treat liver cirrhosis, humoral factors such as cytokines and growth factors produced by MSCs are thought to support lysis of excessive extracellular matrix causing fibrosis, proliferation of hepatocytes, activation of hepatic progenitor cells, suppression of inflammatory response, etc. Shionogi has acquired domestic development and marketing rights on ADR – 001 and entered for the first time in a cell technology program.

Shionogi news release, September 13, 2018